Tixagevimab plus cilgavimab, a SARS-CoV-2–neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial. The study, published in The Lancet Respiratory Medicine, is the first to evaluate the intramuscular injection for outpatient treatment; other anti–SARS-CoV-2 […]
Read More
Older age and higher ferritin levels at hospital admission predict severe illness in COVID-related multisystem inflammatory syndrome in children (MIS-C), according to a Canadian multicenter cohort study. The adjusted absolute risk for admission to an intensive care unit (ICU) was 43.6% among children aged 6 years and older and 46.2% […]
Read More
Concentrations of autoantibodies correlate with disease severity. Why do some people get so much sicker than others with acute COVID-19? And what causes the neurological symptoms — anosmia, fatigue, encephalopathy — seen in some patients? A team from Yale employed a new technology for finding autoantibodies to 2770 extracellular and […]
Read More